

**UW-Madison ILL Lending (GZM)
Document Delivery**

728 State Street / Madison, WI 53706
Email: gzmlend@wils.wisc.edu



ILLiad TN: 209277

Journal Title: Journal of neuroendocrinology

Volume: 15

Issue:

Month/Year: 2003

Pages: 811-2

Article Author: Pariante,

Article Title: Depression, stress and the adrenal axis.

OCLC Number:

ISSN/ISBN Number: 0953-8194

**LOCALLY FORWARDED
REQUEST**

Location: Prim

Call #:

Request Date: 8/11/2004 08:31:06 AM

Not Wanted After: Indefinitely

Notes:

Odyssey

receptor
10; 113;
pathways
its, Am
ello S,
ytocin-
n vitro.

19

SUMMARY

Depression is characterized by an over activity of the hypothalamic-pituitary-adrenal (HPA) axis that resembles the neuroendocrine response to stress. These HPA axis abnormalities participate in the development of depressive symptoms. Moreover, antidepressants directly regulate HPA axis function. These novel findings are reshaping our understanding of the causes and treatment of this disabling disorder.

Two hypothetical pathways by which the activation of the HPA axis participates in the development of depression. In Pathway A, the elevated levels of cortisol induce the depressive symptoms (as in Cushing's disease). In Pathway B, the lack of effects of cortisol induces the depressive symptoms (as in Addison's disease).

Neuroendocrinology Briefings

Depression, Stress and the Adrenal axis


Major depression: major importance

Costing more than 30 billion pounds every year in the UK and the US alone, major depression is a significant cause of disability and the most important cause of suicide worldwide. Why should neuroendocrinologists bother with depression? Depression is characterized by an over activity of the hypothalamic-pituitary-adrenal (HPA) axis that resembles the neuroendocrine response to stress. In this Briefing, I will claim that HPA axis hyperactivity is not a mere epiphenomenon of depression, but rather a crucial biological mechanism in the pathogenesis of this disorder and a fundamental target for its successful treatment.

HPA axis activity is governed by the secretion of corticotropin-releasing hor-

mone (CRH) from the hypothalamus. CRH activates the secretion of adrenocorticotrophic hormone (ACTH) from the pituitary. ACTH, in turn, stimulates the secretion of glucocorticoids (cortisol in humans) from the adrenal glands. Glucocorticoids interact with their receptors – the corticosteroid receptors – in almost every tissue in the body, and the best known effect is the regulation of energy metabolism. By binding to corticosteroid receptors in the brain, glucocorticoids also inhibit the further secretion of CRH from the hypothalamus and ACTH from the pituitary (negative-feedback).

Three lines of evidence demonstrate the link between stress, depression and the HPA axis. First, depression, in its core symptoms of dysphoric or low mood, inability to take pleasure and low energy, is a universal cross-cultural response to stressful events, particularly



Neuroendocrinology Briefings 19

Depression, Stress and the Adrenal axis

19
when the stress is chronic or the individual has to cope over the long term. Second, stress activates the HPA axis, leading to a potential release of corticoids into the bloodstream, depression, especially when severe, is also characterized by over activity of the HPA axis. Thus treatments that dampen the stress response, such as 'talking therapies' improving the ability to cope with stress, have an antidepressant effect; moreover, known antidepressants directly decrease HPA axis activity.

Facts and questions

The HPA axis abnormalities in patients with major depression are remarkably similar to those present in animals experiencing chronic stress. Depressed patients have an increased drive to the HPA axis, as shown by the larger production of CRH in the brain. They also have an impaired negative-feedback by glucocorticoids. Finally, they have an increased volume of the adrenal and pituitary glands. One accepted explanation for the HPA axis over activity in depression is that, because of the reduced function of the corticosteroid receptors, circulating cortisol is unable to successfully inhibit HPA axis activity ('glucocorticoid resistance'). Consistent with this, antidepressants directly increase the expression and function of corticosteroid receptors in the brain, thus enhancing the negative-feedback and reducing HPA axis activity.

'One way to conceptualize depression is a pathological stress response gone awry'
Charles B. Nemeroff, 1996

There is, however, a big unanswered question. Does the fact that depressed patients have a hyperactive HPA axis actually mean that a lot of cortisol is flooding their brain, and that the depressive symptoms are a consequence of this putative 'toxic' effect of cortisol (Pathway A in figure)? Or is the opposite true: that patients have a hyper-

active HPA axis as a compensatory mechanism, because their brain is resistant to the effects of circulating cortisol (Pathway B in figure)? The question is not trivial, especially in our quest for a more effective treatment. In the first scenario, our recommendation should be the lowering of cortisol levels. In the second scenario, our recommendation should be the administering of more cortisol. The situation is complicated by the fact that increased cortisol levels in the bloodstream do not necessarily translate into increased effects of glucocorticoids on the brain, because the brain sensitivity to cortisol is also regulated by the function of the corticosteroid receptors as well as by efflux systems at the blood-brain barrier. In what seems to be a clear effort of nature to tease us all, depression has been described in endocrine disorders characterized by elevated cortisol levels, such as Cushing's disease, but also in disorders characterized by low cortisol levels, such as Addison's disease. Moreover, high and low levels of cortisol give similar functional and morphological changes in the brain. Even more strikingly, both the lowering of cortisol levels and the administering of cortisol have antidepressant effects in depressed patients.

Hero or villain?

Why should the stress-induced activation of the HPA axis, a biological system that is life saving and enables us to fight or escape our enemy, lead to such a bad thing as depression? The answer, from an evolutionary point of view, is that depression – if you are a fawn in a cold barren land, or a defeated gorilla that has fallen in the dominance hierarchy – is an adaptive response. Depression stops you dispersing energy in the pursuing of unavailable goals, prevents further aggressive behaviour from the dominant animals, and signals your difficulty. Today, an increasing number of researchers believe that the stress-induced HPA axis activation directly

causes depressive symptoms, by interacting with the brain neurotransmitter systems regulating these behavioural changes. This idea is further supported by clinical studies showing that normalization of HPA activity by antidepressants precedes the therapeutic effects on the depressive symptoms. While the exact mechanism of this effect is still unknown – and we are divided on whether cortisol is a hero or is a villain – the galloping development in this research field is already changing our understanding of neurobiology and our clinical practice.

Author

Carmine M. Pariante
Institute of Psychiatry
King's College London
London, UK

All communications to the editor

Dr R John Bicknell
Laboratory of Neuroendocrinology
The Babraham Institute
Cambridge CB2 4AT, UK

The Briefings series is intended as a resource to be freely used for teaching and public communication of neuroendocrinology

The full Neuroendocrinology Briefings series can be viewed at website
<http://www.neuroendo.org.uk>